Filing Flows › Haemonetics (HAE) › Who owns the stock
Who owns Haemonetics (HAE) stock
318 funds reported Haemonetics (HAE) shares in their latest 13F filings, worth $4.0B in all. The largest holder is BlackRock ($443M). Last quarter 141 funds added to their stakes and 152 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 5,909,258 | $443M | increase | 2026-06-30 |
| Vanguard Group | 4,761,135 | $382M | decrease | 2025-12-31 |
| Neuberger Berman Group LLC | 4,179,443 | $313M | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 2,546,394 | $191M | decrease | 2026-06-30 |
| AQR Capital Management LLC | 2,266,489 | $165M | decrease | 2026-06-30 |
| Ariel Investments, LLC | 2,060,966 | $155M | new | 2026-06-30 |
| Vanguard Capital Management LLC | 2,059,578 | $154M | decrease | 2026-06-30 |
| State Street | 1,818,186 | $136M | increase | 2026-06-30 |
| Dimensional Fund Advisors LP | 1,585,222 | $119M | increase | 2026-06-30 |
| Citadel Advisors LLC | 1,510,120 | $113M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 1,287,240 | $96.6M | increase | 2026-06-30 |
| Arrowstreet Capital, Limited Partnership | 1,155,351 | $86.7M | decrease | 2026-06-30 |
| T. Rowe Price Investment Management | 1,101,371 | $82.6M | increase | 2026-06-30 |
| Goldman Sachs Group | 1,046,019 | $78.5M | increase | 2026-06-30 |
| UBS Group AG | 983,378 | $73.8M | increase | 2026-06-30 |
Haemonetics' latest quarter
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most HAE stock?
By the latest 13F filings: BlackRock ($443M); Vanguard Group ($382M); Neuberger Berman Group LLC ($313M); Vanguard Portfolio Management LLC ($191M); AQR Capital Management LLC ($165M).
What is the short interest in HAE?
3,428,091 shares were sold short at the 2026-10-15 settlement, 12.85% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.